Novel therapeutic approaches for COVID-19 in chronic kidney disease and transplant

Curr Opin Nephrol Hypertens. 2021 Jan;30(1):47-53. doi: 10.1097/MNH.0000000000000671.

Abstract

Purpose of review: Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) is the novel virus responsible for the current worldwide pandemic. The scientific and healthcare communities have made every effort to discover and implement treatment options at a historic pace. Patients with kidney disease are uniquely vulnerable to an infectious pandemic because of their need to be in frequent contact with the healthcare system for life-sustaining renal replacement therapy whether it be by dialysis or transplant.

Recent findings: The use of targeted viral therapies, extracorporeal therapies, immunosuppressive therapy and public health interventions are important in the management of patients with COVID-19 but require special consideration in patients with kidney disease because of the complexity of their condition.

Summary: Here, we discuss some of the major efforts made to prevent spread and emerging treatment options for this virus, as they pertain to patients with kidney disease.

Publication types

  • Review

MeSH terms

  • Antiviral Agents / therapeutic use
  • COVID-19 / immunology
  • COVID-19 / therapy*
  • COVID-19 Vaccines / immunology
  • Humans
  • Kidney Transplantation*
  • Renal Insufficiency, Chronic / therapy*
  • SARS-CoV-2*

Substances

  • Antiviral Agents
  • COVID-19 Vaccines